anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an antiviral compound derived from a black fungus strain, and a preparation method and application thereof. The invention provides application of a compound or pharmaceutically acceptable salt thereof in preparing a virus inhibitor or an antiviral drug. The present invention also protects the compounds. The invention also provides a preparation method of the protective compound, which comprises the following steps: fermenting and culturing the strain CPCC 400972 of the genus Leuconostoc to obtain the compound. The optical black shell strain CPCC 400972 has a preservation registration number of CGMCC No.21069. The compound is a compound shown in a formula (I) or a compound shown in a formula (II). The invention has great application and popularization value for prevention and control of viruses and prevention and control of diseases caused by viruses.
The spectrum of childhood leukemia predisposition syndromes has grown significantly over last decades. These predisposition syndromes mainly involve CEBPA, ETV6, GATA2, IKZF1, PAX5, RUNX1, SAMD9/SAMD9L, TP53, RAS-MAPK pathway, DNA mismatch repair system genes, genes associated with Fanconi anemia, and trisomy 21. The clinico-biological features leading to the suspicion of a leukemia predisposition are highly heterogeneous and require varied exploration strategies. The study of the initial characteristics of childhood leukemias includes high-throughput sequencing techniques, which have increased the frequency of situations where a leukemia predisposing syndrome is suspected. Identification of a leukemia predisposition syndrome can have a major impact on the choice of chemotherapy, the indication for hematopoietic stem cell transplantation, and screening for associated malformations and pathologies. The diagnosis of a predisposition syndrome can also lead to the exploration of family members and genetic counseling. Diagnosis and management should be based on dedicated and multidisciplinary care networks.
This is the institutional standard of care. The evening before surgery, 20 subjects will reduce their basal insulin dose to 50%.
Subjects in control group received simple lifestyle advice from a clinician at baseline and month 6. This was a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects were encouraged to perform regular 30-minute exercise 2 to 3 times per week. This was to resemble routine clinical practice.
PURPOSE:Overcoating for lipstick not damaging color of lipstick, preventing adhesion of lipstick to tablewares, etc., having improved durability of makeup effect, no making profile of lipstick unclear with time, not causing spreading of color, comprising a component consisting essentially of powder blended with an oily component. CONSTITUTION:Overcoating comprising power blended with an oily component as a main component. The powder has especially a transparent feeling not to damage color of lipstick, making preferably a film of powder with a thin feeling during coating, inorganic powder such as talc, zinc white, kaolin, mica, etc. and organic powder such as nylon powder, polyethylene powder, etc. are used as the powder, and it can be blended with pearl pigment, coloring pigment, etc. For example, aliphatic hydrocarbon, animal or vegetable oil, higher fatty acid or ester, higher alcohol, silicon oil, etc. may be cited as the oily component. An amount of the oily component blended is preferably 5-25wt% in the product.
The aim of this trial is to study the effects of antihypertensive therapy based on home systolic blood pressure (BP) with different target levels using two classes of drugs.

The HOSP study is a multicenter, prospective, randomized, open, blinded endpoint study. Inclusion criteria are 40-79 years old treated or untreated hypertensive patients without serious medical conditions. After a 4 weeks of baseline period, subjects are randomly assigned to (1) modest control group (target morning home BP \<140 mmHg) or (2) strict control group (morning home BP \<130 mmHg), and to (a) amlodipine group (2.5-5 mg od) or (b) losartan group (25-50 mg od). Additional antihypertensive drugs (diuretics, beta-blockers and alpha-blockers) can be used if home BP is not controlled. Home BP is measured in the early morning and late evening. Primary end point is combined cardiovascular events.The participants will be followed up for 5 years.
PROBLEM TO BE SOLVED: To obtain the subject cyclic dipeptide-containing composition that can improve stability of medicines, cosmetics, food products and the like, particularly their stability at a temperature near the body temperature by admixing a specific compound to these products. SOLUTION: 1,3,5-Benzenetricarboxylic acid having the stereostructure responding to the compound to be prepared is allowed to react with thionyl chloride and the resultant acid chloride is allowed to react with the corresponding alkylamine or alkenylamine, and the product is purified, when necessary, to form an aspartic acid-phenylalanine cyclic dipeptide derivative of formula I [R is a 8-22C (cyclic structure-including) straight or branched alkyl or alkenyl] typically cyclo(L-β-dimethyloctylasparaginyl-L-phenylalanine). This compound is admixed to cosmetics, medicines and the like, particularly of high content of oily components. The amount of the compound of formula I is preferably 0.1-100 pts.wt. per 1 pt.wt. of the oily component.
INTRODUCTION: Renal cell carcinoma (RCC) is a common malignancy known for its potential to invade the venous system, particularly the inferior vena cava (IVC), leading to tumor thrombus (TT) formation. While the presence of TT in RCC isn't unique, extension of TT above the diaphragm is rare. This case highlights the challenges encountered in diagnosing and managing RCC with extensive TT involvement.
CASE REPORT: A 69-year-old man presents with 3-month history of dyspnea and increasing fatigue in the setting of 30 pounds weight loss. Laboratory studies showed anemia and acute kidney injury. CT abdomen and pelvis revealed 6.8cm solid mass within the left perinephric space, enlarged IVC with large thrombus. Kidney biopsy returned positive for clear cell renal carcinoma with metastasis to the liver. Several days into the hospitalization the patient began to experience increased abdominal pain. Repeat ultrasound showed tumor thrombus with extension within the intrahepatic IVC and hepatic veins and reversal of portal venous flow. During the imaging study, the patient suffered a cardiac arrest and expired. Postmortem examination revealed diffuse showering of tumor emboli within the pulmonary arteries, likely contributing to the patient's rapidly progressive respiratory failure, and subsequent cardiovascular collapse.
CONCLUSION: This case illustrates the complexity of treating patients with extensive TT. In patients with RCC associated TT, the risk for thromboembolism is increased substantially, however the full benefit of anticoagulation remains controversial. Understanding the intricacies of TT involvement and its potential complications is crucial in guiding treatment decisions in patients with significant tumor thrombus burden.
ARM B will 12 weeks of FTC/TDS standard of care (SOC) first. At 12-week intervals participants will crossover to the next condition.
FIELD: animal science. SUBSTANCE: the present innovation deals with supplementing the diet with probiotic preparation manufactured based upon somatoliberin-expressing recombinant Lactobacillus sp. 8PA3 (pLF-SL2) strain in digestive tract. The method enables to increase milk and meat performance in animals and improve the quality of production, that is: increase protein concentration in milk, increase the portion of muscular tissue and decrease fat content in meat. EFFECT: higher performance and improved quality of production. 4 ex, 5 tbl
PROBLEM TO BE SOLVED: To obtain an antifungal agent capable of curing a fungus disease by including a guanidinyl derivative. SOLUTION: This antifungal agent contains a compound of the formula (R is H or guanidinyloctylcarbonyl) [e.g. 1,13-bis(guanidinyl)-4-(8- guanidinyloctylcarbonylamino)-5-hydroxytridecane] as an active component. The compound of the formula is effective in curing superficial fungus diseases such as trichophytoniasis, Malassezia furfur and sporotrichosis, and visceral fungus diseases such as Aspergillusis. The compound of the formula is obtained by culturing Streptomyces sp. POL-1142 belonging to a Streptomyces genus and purifying the cultured product with a chromatography. The antifungal agent can control not only growth of Eumycetes but also inflammation caused by Eumycetes.
Mechanism of Action: Mefloquine is an antimalarial agent which acts as a blood schizonticide. Its exact mechanism of action is not known.

Activity In Vitro and In Vivo: Mefloquine is active against the erythrocytic stages of Plasmodium species (see INDICATIONS AND USAGE). However, the drug has no effect against the exoerythrocytic (hepatic) stages of the parasite. Mefloquine is effective against malaria parasites resistant to chloroquine (see INDICATIONS AND USAGE).

Drug Resistance: Strains of P. falciparum with decreased susceptibility to mefloquine can be selected in vitro or in vivo. Resistance of P. falciparum to mefloquine has been reported in areas of multi-drug resistance in South East Asia. Increased incidences of resistance have also been reported in other parts of the world.

Cross-Resistance: Cross-resistance between mefloquine and halofantrine and cross-resistance between mefloquine and quinine have been observed in some regions.
A dental composition for the treatment of dentinal hypersensitivity and in particular for the desensitization of exposed dentin, the desensitizing treatment of deep cavities, the desensitizing treatment when replacing dental layers, the stumps desensitizing treatment before placing dental prosthesis. The composition can be used as a solution or as a gel. In the first case two distinct liquid solutions for use successively on the exposed dentin are provided for. In the second case two distinct gel compounds spread successively on the exposed dentin are provided for. The first solution or the first gel compound comprises preferably three soluble potassium salts, whereas the second solution or the second gel compound comprises a calcium salt and a soluble strontium salt. In a preferred composition two solutions are provided for of which the first has solutes comprising potassium phosphate, potassium carbonate and potassium fluoride, and the second solution has solutes comprising calcium chloride and strontium chloride. For the gel composition, which may be used as toothpaste, two distinct gel compounds are provided, the first having solutes comprising potassium phosphate, potassium carbonate and potassium fluoride and the second gel compound having solutes comprising calcium chloride and strontium chloride.
The purpose of this study is to evaluate the mechanical strength of various staple line reinforcement techniques using the resected portion of stomach in patients undergoing laparoscopic sleeve gastrectomy. The specimen will be collected at the time of surgery, the previous staple line will be excised, and a new staple line with one of the investigatory reinforcement procedures will be applied. The staple line techniques to be used in this study include non-buttressed and non-imbricated oversewing, non-buttressed and imbricated suture line, buttressed stapling, and no reinforcement (see protocol for description of each). The specimen will then be taken to the morgue where the experimental procedure will be performed within 6 hours of specimen procurement. The specimen will be attached to a catheter with a pressure monitor and blue dye will be instilled into the specimen until leakage is seen. The presence of leakage indicates failure of the staple line. Detailed measurements of all specimens will be performed as will leak pressure and location in the specimen where leak occurred. The specimen will then be turned over to pathology to undergo routine pathologic examination.

This experimental procedure has been used previously in published literature with animal samples, but never with human tissue. A possible reason for the lack of testing in the stomach staple line in patients after sleeve gastrectomy is that the technical aspects of bariatric surgery were developed using gastric bypass; a procedure where the stomach is divided but not excised.

The investigators hypothesize that the specimens treated with staple line buttressing material will fail at a higher pressure than those without reinforcement. The investigators will also explore the location of the failure to determine if there is a consistent site of weakness. Should this study yield consistent results, it would help determine a standard approach for staple line reinforcement after laparoscopic sleeve gastrectomy. Additionally, should the location of the leak be consistent, this information may help drive technical changes that could decrease leak rate, an infrequent but potentially devastating risk of this and other weight loss surgeries.
Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m\^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
Maxillary occlusal splints are made of hard acrylic after taking impressions of the upper dental arches, recording of centric relation (Okeson). Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night at least 8 hours/day for a period of 8 weeks. In addition, patients are still instructed CBT as group 1.
According to the 2013 Global Burden of Disease study, recurrent tension-type headache is the second most common chronic disease worldwide, with an age-standardized prevalence of 21.75 % (1). Although high prevalence of chronic tension-type headache (CTTH) has been reported in all world regions, it is also the most neglected disorder and it leads to headaches that are difficult to treat (2). Myofascial pain can play an important etiologic role. It has been claimed that pain from pericranial head, neck and shoulder muscles is associated with the head and experienced as headache (5, 6). Within the cervical musculature, there are several head and neck muscles, eg. temporal, masseter, upper trapezius, sternocleidomastoid, temporalis, sub-occipital muscles, from which trigger points (TrPs) spread referred pain to the head (6). There are several pharmacological and non-pharmacological therapies for patients with CTTH. Physiotherapy is the most commonly used non-pharmacological treatment of CTTH. Although sports and orthopedic physiotherapists have used dry needling (DN) for a long time to address the pain and dysfunction associated with myofascial trigger points (11), there is insufficient evidence to strongly advocate for use of DN for treatment of CTTH (12). In this double-blind randomized trial, we aimed to explore the effectiveness of trigger point dry needling in patients with CTTH in reduction of headache frequency, intensity, duration, and improve health-related quality of life (HRQoL).
Maintaining functional adipose innervation is critical for metabolic health. We found that subcutaneous white adipose tissue (scWAT) undergoes peripheral neuropathy (PN) with obesity, diabetes, and aging (reduced small-fiber innervation and nerve/synaptic/growth-cone/vesicle markers, altered nerve activity). Unlike with nerve injuries, peripheral nerves do not regenerate with PN, and therefore new therapies are needed for treatment of this condition affecting 20-30 million Americans. Here, we validated a gene therapy approach using an adipocyte-tropic adeno-associated virus (AAV; serotype Rec2) to deliver neurotrophic factors (brain-derived neurotrophic factor [BDNF] and nerve growth factor [NGF]) directly to scWAT to improve tissue-specific PN as a proof-of-concept approach. AAVRec2-BDNF intra-adipose delivery improved tissue innervation in obese/diabetic mice with PN, but after longer periods of dietary obesity there was reduced efficacy, revealing a key time window for therapies. AAVRec2-NGF also increased scWAT innervation in obese mice and was more effective than BDNF, likely because Rec2 targeted adipocytes, the tissue's endogenous NGF source. AAVRec2-NGF also worked well even after 25 weeks of dietary obesity, unlike BDNF, which likely needs a vector that targets its physiological cellular source (stromal vascular fraction cells). Given the differing effects of AAVs carrying NGF versus BDNF, a combined therapy may be ideal for PN.
PURPOSE:To obtain the subject monoclonal antibody, specifically reactive with an isozyme of brain myosin and useful for diagnosing, etc., cerebral neuropathy such as various cerebral tumors, senile encephalatropy or Alzheimer type encephalatropy causing a change in quality of cerebral neurons. CONSTITUTION:Bovine cerebral myosin is dissolved in a 0.5M saline solution and mixed with complete Freund's adjuvant at 1:1 ratio and the resultant emulsion is then subcutaneously injected to immunize a BALB/c mouse. After 9 days, lymph nodes in both popliteal fossa parts of the mouse are taken out to collect a lymphocyte therefrom. The resultant lymphocyte is then fused to a murine myeloma. The fused cell is cultured in an HAT culture medium to provide a hybridoma, which is then screened to select an antibody-producing clone. The selected clone is further cloned by a limiting dilution method, etc., and monocloned. The resultant monoclonal hybridoma is cultured in a culture medium to afford the objective monoclonal antibody specifically reactive with an isozyme of the brain myosin.
The study will include 1500 children with type 1 diabetes, aged 6-18 years. These will be patients from Diabetes Outpatient Clinics and patients hospitalized in Departments of Paediatrics, Endocrinology and Diabetology in University and Municipal Hospitals from Poland (Białystok, Warszawa, Łódź, Gdańsk, Wrocław, Katowice).
FIELD: medicine. ^ SUBSTANCE: invention refers to cosmetics, namely to creation of new cosmetic face oil compositions encapsulated and presented in the form of softgel capsules that is the a single dosage form. The cosmetic face oil composition contains mixed vegetable oils, wt %: sesame oil 15-17, water-melon seed oil 9-13, walnut oil 8-10, peach oil 9-11, apricot oil 8-10, jojoba oil 2-3, lemon essence 2-3, olive oil - the rest to be encapsulated in the form of softgel capsules that is a single dosage form. This enables to increase shelf-life and retaining properties of the oils. ^ EFFECT: use of the offered composition provides rejuvenation and prevention of premature ageing, ability of skin to smoothing, active nourishment, eliminated desquamation, restored moisture-retaining power, intensified immune status of skin. ^ 1 cl, 2 tbl
The dosage of the Apri Tablet 28-Day Regimen for the initial cycle of therapy is one tablet administered daily from the 1st day through 21st day of the menstrual cycle, counting the first day of menstrual flow as “Day 1”. Tablets are taken without interruption as follows: One rose-colored tablet daily for 21 days, then one white tablet daily for 7 days. After 28 tablets have been taken, a new course is started and a rose-colored tablet is taken the next day.

The use of the Apri Tablet 28-Day Regimen for contraception may be initiated 4 weeks postpartum in women who elect not to breast feed. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered. (See CONTRAINDICATIONS and WARNINGS concerning thromboembolic disease. See also PRECAUTIONS for “Nursing Mothers.”) If the patient starts on Apri tablets postpartum, and has not yet had a period, she should be instructed to use another method of contraception until a rose-colored tablet has been taken daily for 7 days. The possibility of ovulation and conception prior to initiation of medication should be considered. If the patient misses one (1) active tablet in Weeks 1, 2, or 3, the tablet should be taken as soon as she remembers. If the patient misses two (2) active tablets in Week 1 or Week 2, the patient should take two (2) tablets the day she remembers and two (2) tablets the next day; and then continue taking one (1) tablet a day until she finishes the pack. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills. If the patient misses two (2) active tablets in the third week or misses three (3) or more active tablets in a row, the patient should throw out the rest of the pack and start a new pack that same day. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills.
To give a clear emulsifying of healing plant extracts, in cold-pressed olive oil, plate disks are rotated at high speeds in a fluid mixing mill/mixer. Two or more specially twisted disks, overlapping at their ends, are used with positioned magnets. High speed motors are operated at different rotary speeds of 10-10000 rpm. Within the mixing vessel the magnets are placed to generate magnetic fields when like polarities cross, to give a spin and eddy movement to the mixture. The mixture to be emulsified is hermetically sealed in a mill/mixing container. The rotating disks are notched at their edges to give a molecular eddy action to the liquids, as well as the magnetic field spin action to emulsify and bond the liquid components without a chemical action between them. The liquids and the emulsions are fed and extracted in hermetically sealed channels, to prevent contact with oxygen or oxidizing. Permanent and/or electromagnetic fields at the outlet give the emulsion an aging process in a short time span.
This study is a preliminary clinical study about safety of artificial salivary containing cumin and ginger extract in 21 healthy volunteers. The volunteers will be divided into 3 groups which are artificial salivary containing 0.3% cumin and 0.05%ginger extract group, artificial salivary containing 0.3%cumin and 0.1%ginger extract group, and artificial salivary containing 0.3%cumin and 0.15%ginger extract group. The volunteers will be evaluated salivary volume by Schirmer test, salivary acid and base value by strip test, dry mouth by questionnaire, and adverse effects before and after using the artificial salivary for 30 min. After the preliminary clinical study, safety of artificial salivary containing cumin and ginger extract in 112 healthy volunteers. The volunteers will be divided into 2 groups which are artificial salivary containing cumin and ginger extract group and commercial artificial salivary. The volunteers will be evaluated salivary acid and base value by strip test and adverse effects by World Health Organization Oral Mucositis Grading Scale and questionnaire before and after using the artificial salivary (3 times/day) for 3 and 6 days. Then, the volunteers will stop using the artificial salivary for 7-10 days. After that, the volunteers will be used the artificial salivary for 3 days. All evaluation will be tested.